Synovial incorporation of polyacrylamide hydrogel after injection into normal and osteoarthritic animal joints

Polyacrylamide hydrogel (PAAG) is a non-toxic, non-degradable synthetic product, used for years in the augmentation of soft tissues. Preliminary results in animals and humans have suggested long-lasting beneficial effects on symptoms of osteoarthritis (OA). The aim of this histopathological study was to investigate whether intra-articular injection of PAAG is integrated into synovial tissue in normal and OA animal joints, and if this integration is sustained.(A) A prospective, controlled, longitudinal study of normal knee joints injected with PAAG was performed in 10 rabbits, following the animals up to 1 year, and (B) a post mortem examination was carried out up to 2 years post-injection on 18 horse joints which had previously been treated with 1-2 injections of 2 ml PAAG for clinically and radiologically diagnosed OA.Integration of the injected gel was evident at day 10 in the rabbit and by day 14 in the horse, with proliferation and invasion of synovial cells into the gel. By day 90 in rabbit joints and day 30 in horse joints, the gel had formed a sub-synovial layer, which was traversed by thin strands of connective tissue with vessels and covered by a synovial lining facing the joint cavity. This histological appearance persisted up to 2 years post-injection in horse joints.Intra-articular injection of PAAG results in a stable, long-lasting sub-synovial layer of gel traversed with thin strands of connective tissue. Further studies to explore potential effects on synovial inflammation and pain are warranted

Polyacrylamide Hydrogel Injection for Knee Osteoarthritis: A 6 Months Prospective Study

Objective: Intra-Articular (IA) injection of polyacrylamide hydrogel (PAAG) is a possible treatment for symptomatic Osteoarthritis (OA) of the knee. This study evaluated the efficacy and safety of a single injection of 6 ml intra-articular PAAG over 26 weeks. Methods: Open-label study in patients with symptomatic and radiographically confirmed knee OA . Primary outcome was change in WOMAC pain after 13 weeks. Secondary outcomes were WOMAC stiffness and function subscales, Patient Global Assessment of disease impact (PGA) and proportion of OMERACT-OARSI responders. Follow-up time points were 4, 13 and 26 weeks. Results: 49 patients (31 females) received PAAG, with 48 patients completing the 13 and 46 the 26 weeks assessments. Mean change in WOMAC pain after 13 weeks was -18.3 points [95% CI-23.4 to -13.3]; P<.0001 and at 26 weeks -20.8 points [95% CI -26.3 to -15.3]; P<0.0001 with similar benefits for WOMAC stiffness, physical function, and PGA. After 13 weeks 64.6% were OMERACT-OARSI responders and this was maintained at 26 weeks.. During the 13 weeks, 18 patients reported 23 adverse events, 13 of which were related to PAAG, none severe. Two serious adverse events, atrial fibrillation and gastrointestinal pain, were assessed as ‘not related’ to PAAG. Conclusions: PAAG can be delivered in a single 6 ml injection and this non-randomized trial in patients with knee OA demonstrated beneficial clinical effects at 13 and 26 weeks. No serious adverse events were seen with PAAG. These encouraging results need to be confirmed in controlled studies

Effect of Neuromuscular Electrical Muscle Stimulation on Energy Expenditure in Healthy Adults

Weight loss/weight control is a major concern in prevention of cardiovascular disease and the realm of health promotion. The primary aim of this study was to investigate the effect of neuromuscular electrical stimulation (NMES) at different intensities on energy expenditure (oxygen and calories) in healthy adults. The secondary aim was to develop a generalized linear regression (GEE) model to predict the increase of energy expenditure facilitated by NMES and identify factors (NMES stimulation intensity level, age, body mass index, weight, body fat percentage, waist/hip ratio, and gender) associated with this NMES-induced increase of energy expenditure. Forty sedentary healthy adults (18 males and 22 females) participated. NMES was given at the following stimulation intensities for 10 minutes each: sensory level (E1), motor threshold (E2), and maximal intensity comfortably tolerated (E3). Cardiopulmonary gas exchange was evaluated during rest, NMES, and recovery stage. The results revealed that NMES at E2 and E3 significantly increased energy expenditure and the energy expenditure at recovery stage was still significantly higher than baseline. The GEE model demonstrated that a linear dose-response relationship existed between the stimulation intensity and the increase of energy expenditure. No subject’s demographic or anthropometric characteristics tested were significantly associated with the increase of energy expenditure. This study suggested NMES may be used to serve as an additional intervention for weight loss programs. Future studies to develop electrical stimulators or stimulation electrodes to maximize the comfort of NMES are recommended

Influence of knee joint angle on muscle properties of paralyzed and nonparalyzed human knee extensors

Muscles of individuals with a spinal cord injury (SCI) exhibit an unexpected leftward shift in the force (torque)-frequency relationship. We investigated whether differences in torque-angle relationships between SCI and able-bodied control muscles could explain this shift. Electrically stimulated knee-extensor contractions were obtained at knee flexion angles of between 30° and 90°. Torque-frequency relationships were obtained at 30°, 90°, and optimum angle. Optimum angle was not different between groups but SCI-normalized torques were lower at the extreme angles. At all angles, SCI muscles produced higher relative torques at low stimulation frequencies. Thus, there was no evidence of a consistent change in the length of paralyzed SCI muscles, and the anomalous leftward shift in the torque-frequency relationship was not the result of testing the muscle at a relatively long length. The results provide valuable information about muscle changes occurring in various neurological disorders. © 2005 Wiley Periodicals, Inc